New Treatment for Oral Mucositis in Cancer: Dr. Pierre Morgon, Ibex Therapeutics

The pain in your mouth is so bad that you cannot even drink, let alone eat.What is horrifying is that 50-80% of cancer patients undergoing chemo or radiotherapy can experience it – oral mucositis.And there is no approved treatment.This is what you’ll hear in this episodehow a cute-looking willowherb grown in the Swiss Alps is making its way from traditional medicine to prescription medicine – to treat oral mucositis, especially in cancer patientsand in the long term, more broadly – fungal infectionsMy guest today is Dr. Pierre Morgon, the CEO of Ibex Therapeutics. With a PhD in pharmacy, he has held numerous senior positions in the life sciences industry and currently serves on the boards of biotech, medtech, and healthcare IT startups.He decided to co-found Ibex Therapeutics, a Swiss startup that aims to alleviate the debilitating oral pain that often results from chemotherapies and radiotherapies. To combat oral mucositis, they employed a plant native to the Swiss Alps.Here’s more about them if you’re curious:https://ibextx.ch/en/Timestamps:0:00 Dr. Pierre Morgon and Ibex Therapeutics1:18 Willowherb from the Swiss Alps3:00 What is Oral Mucositis11:01 Discovery of Epilobium Parviflorum Antifungal Properties: the Discovery 20:49 Clear Unmet Need + Experienced Founders25:32 Mouth Wash for Oral Mucositis: First Studies in Patients33:34 Market Availability: Cosmetic and Pharmaceutical Products43:15 Plant-Based Medicine49:02 Thank You, Follow Ibex Therapeutics 49:34 Follow X-Health.show, Disclaimer If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.